Pipeline Expansion Mapi Pharma has a diverse pipeline of long-acting depot injection treatments targeting high-value markets such as multiple sclerosis, diabetes, Parkinson’s disease, and psychiatric disorders, presenting numerous opportunities for partnerships and commercialization deals.

Strategic Partnerships The company has established collaborations with industry leaders like Mylan/Viatris and partners like Shavit Capital, indicating a strong openness to licensing, co-development, and strategic alliances that can accelerate market entry and expand product reach.

Clinical Validation Mapi Pharma consistently demonstrates efficacy and safety through high-profile conferences and clinical studies, reinforcing the credibility of its innovative depot products and enhancing attractiveness to healthcare providers and payers.

Regional Presence With R&D facilities and manufacturing units in Israel, along with active participation in international medical conferences, Mapi Pharma is well-positioned to engage global markets and establish distribution channels for its advanced injectable therapies.

Financial Growth Boasting revenues between 25 and 50 million USD and recent funding of 20 million USD, Mapi Pharma is advancing towards commercialization readiness, making it a promising partner for investors and distributors seeking growth opportunities.